NTSR1 and central nervous system cancer: To evaluate the potential of GALV-RRV as a therapeutic agent for glioma therapy, we incorporated the yeast cytosine deaminase (CD) [23] or E. coli nitroreductase (NTR) [24,25] prodrug activator genes into this type of vector.